Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Analyst Ratings
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18
Foghorn Therapeutics Analyst Ratings
Evercore ISI Group Initiates Coverage On Foghorn Therapeutics With Outperform Rating, Announces Price Target of $20
Evercore Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
Evercore Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $20
Foghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy Rating
HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Analyst Ratings
Wedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
HC Wainwright & Co. : The Foghorn Therapeutics (FHTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.